Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address ...

The U.S. digital therapeutics market size was valued at $1.16 billion in 2019 and is expected to reach $5.08 billion by 2027 with a CAGR of 19.2% during the forecast period. Increase in adoption of ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, is entering the second quarter of its financial year with "clear momentum", despite the first quarter being ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. The FDA has approved the ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $157.00. The company’s ...

This study reviews the literature on digital therapeutics for CIAS, examines the challenges, and offers recommendations for advancement from the perspective of computer science and technology.

Our digital therapeutics and pharmacy services are designed to meet patients where they are, breaking down barriers to recovery. “Participating in the Rx and Illicit Drug Summit is an important ...

Digital therapeutics (DTx) is a subset of digital health that uses software to treat medical conditions and improve patient outcomes. DTx products are designed to deliver evidence-based interventions ...

Attendees can connect with the PursueCare team at Booth #422 to explore innovative digital health solutions for substance use disorder (SUD) and opioid use disorder (OUD).